Bio tech company updates — 7/9/2026
Korean biotech stocks face severe headwinds as capital flows shift toward AI chips and policy-driven sectors, with major companies like Yuhan recording significant divergence from price targets. The sector struggles with structural challenges including heavy licensing dependencies, while biopharmaceutical exports remain robust at record-setting levels. ABL Bio accelerates partnerships as the industry eyes major pharma deals despite market volatility.
2 min read/15 sources
